Due to the unexpectedly slow rollout of controversial Alzheimer’s drug Aduhelm, Biogen executives are facing the possibility of spending cuts and layoffs. As of mid-September, only about 100 patients had received the drug. (STAT)

Luxturna developer Jean Bennett has launched her own company, Opus Genetics, which will focus on gene therapies for ultra-rare eye diseases. The company has  secured $19 million in funding, largely from the Retinal Degeneration Fund. (Endpoints News)

Global health officials are pressuring Moderna to share its COVID-19 vaccine technology with nations that desperately need it. Fewer than 10% of people in low-income countries have been fully vaccinated. (The New York Times)

COVID-19 peak seasons will become an annual occurrence as the pandemic transitions to an endemic state, former Food and Drug Administration head Dr. Scott Gottlieb said. Paired with the annual flu season, COVID peaks could cost businesses billions of dollars a year. (CNBC Weekly)

Obsessive-compulsive disorder therapy startup NOCD has raised $33 million. It’s one of several mental health-focused companies that are focusing on specific conditions. (Business Insider)